• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

C-原癌基因在人良性和恶性肾组织中的表达

C-met proto-oncogene expression in benign and malignant human renal tissues.

作者信息

Pisters L L, el-Naggar A K, Luo W, Malpica A, Lin S H

机构信息

Department of Urology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

出版信息

J Urol. 1997 Sep;158(3 Pt 1):724-8. doi: 10.1097/00005392-199709000-00009.

DOI:10.1097/00005392-199709000-00009
PMID:9258068
Abstract

PURPOSE

Hepatocyte growth factor/scatter factor (HGF/SF) is a potent mitogen to renal epithelial cells in vitro and in vivo. HGF/SF signals through its receptor which is coded by the c-met proto-oncogene. We hypothesized that altered expression of the HGF/SF receptor, c-met, may be involved in the pathogenesis of certain renal cell carcinomas. Our objectives were to 1) assess the presence and localization of c-met protein in benign and malignant human renal tissues, and 2) correlate the presence of c-met protein with renal carcinoma histological subtype, tumor stage and tumor grade.

MATERIALS AND METHODS

Immunohistochemical analysis of c-met protein was performed in 41 normal and malignant human renal samples.

RESULTS

c-met Immunostaining was detected in the normal kidney tissue in all 41 samples. In the normal kidney c-met immunostaining was limited to the cell membrane and/or cytoplasm of epithelial cells in specific tubular segments, including the proximal convoluted tubule, thin and thick limbs of the loop of Henle, and the collecting duct. The glomeruli, distal convoluted tubule and stroma were consistently negative for c-met staining. c-met Immunostaining was detected in 68% of renal cell carcinomas and was more common in higher nuclear grade cancers (p < 0.034).

CONCLUSIONS

The c-met receptor is present in specific tubular segments in the normal kidney and is frequently expressed in higher nuclear grade renal cancers, suggesting a role in renal carcinoma progression. Future studies should evaluate the biological significance of the HGF/ SF-c-met pathway in normal renal physiology, and renal cancer growth and progression.

摘要

目的

肝细胞生长因子/离散因子(HGF/SF)在体外和体内都是肾上皮细胞的一种强效促有丝分裂原。HGF/SF通过其由c-met原癌基因编码的受体发出信号。我们推测,HGF/SF受体c-met表达的改变可能参与某些肾细胞癌的发病机制。我们的目标是:1)评估c-met蛋白在良性和恶性人类肾组织中的存在及定位,以及2)将c-met蛋白的存在与肾癌的组织学亚型、肿瘤分期和肿瘤分级相关联。

材料与方法

对41例正常和恶性人类肾样本进行c-met蛋白的免疫组织化学分析。

结果

在所有41个样本的正常肾组织中均检测到c-met免疫染色。在正常肾脏中,c-met免疫染色仅限于特定肾小管节段上皮细胞的细胞膜和/或细胞质,包括近端曲管、髓袢细段和粗段以及集合管。肾小球、远端曲管和间质的c-met染色始终为阴性。在68%的肾细胞癌中检测到c-met免疫染色,在高核分级癌症中更常见(p < 0.034)。

结论

c-met受体存在于正常肾脏的特定肾小管节段中,且在高核分级肾癌中频繁表达,提示其在肾癌进展中起作用。未来的研究应评估HGF/SF-c-met途径在正常肾脏生理学以及肾癌生长和进展中的生物学意义。

相似文献

1
C-met proto-oncogene expression in benign and malignant human renal tissues.C-原癌基因在人良性和恶性肾组织中的表达
J Urol. 1997 Sep;158(3 Pt 1):724-8. doi: 10.1097/00005392-199709000-00009.
2
c-met proto-oncogene expression in benign and malignant human prostate tissues.c-原癌基因在人前列腺良恶性组织中的表达。
J Urol. 1995 Jul;154(1):293-8.
3
Overexpression of the met/HGF receptor in renal cell carcinomas.肝细胞生长因子/分散因子受体在肾细胞癌中的过表达。
Int J Cancer. 1996 Jun 21;69(3):212-7. doi: 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9.
4
Hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), and their receptors in human breast cells and tissues: alternative receptors.肝细胞生长因子(HGF)、角质形成细胞生长因子(KGF)及其在人乳腺细胞和组织中的受体:替代受体
Cell Mol Biol Res. 1994;40(4):337-50.
5
MET expression in sporadic renal cell carcinomas.散发性肾细胞癌中的MET表达。
J Korean Med Sci. 2006 Aug;21(4):672-7. doi: 10.3346/jkms.2006.21.4.672.
6
Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.血管内皮生长因子-B和血管内皮生长因子-C在肾细胞癌中的表达:受希佩尔-林道基因和缺氧调控
Cancer Res. 2001 Apr 1;61(7):3206-11.
7
Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma.肝细胞生长因子及其受体C-甲胎蛋白在与肾细胞癌相关的获得性肾囊肿疾病中的表达
J Urol. 2004 Jun;171(6 Pt 1):2166-70. doi: 10.1097/01.ju.0000124263.51906.b9.
8
Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer.原发性乳腺癌中肝细胞生长因子/分散因子的表达及c-met蛋白
Surg Oncol. 1996 Feb;5(1):15-21. doi: 10.1016/s0960-7404(96)80017-x.
9
Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.通过U1小核RNA/核酶靶向分散因子/肝细胞生长因子和c-met表达逆转人类胶质母细胞瘤的恶性程度
J Natl Cancer Inst. 1999 Sep 15;91(18):1548-56. doi: 10.1093/jnci/91.18.1548.
10
Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes.肝细胞生长因子刺激肾小管有丝分裂:对c-myc、c-fos、c-met、血管内皮生长因子(VEGF)以及VHL肿瘤抑制因子和相关基因表达的影响
Br J Cancer. 1998 May;77(9):1420-8. doi: 10.1038/bjc.1998.235.

引用本文的文献

1
Renal Abscess Caused by Crizotinib: A Rare Case Report.克唑替尼引起的肾脓肿:一例罕见病例报告
Front Oncol. 2022 Jul 7;12:920990. doi: 10.3389/fonc.2022.920990. eCollection 2022.
2
C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas.C-Met 作为维持肾细胞癌未分化表型和治疗耐药的关键因素。
Cells. 2019 Mar 22;8(3):272. doi: 10.3390/cells8030272.
3
Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review.高c-Met表达在肾细胞癌中的临床病理影响:一项荟萃分析与综述
Oncotarget. 2017 Sep 8;8(43):75478-75487. doi: 10.18632/oncotarget.20796. eCollection 2017 Sep 26.
4
c-Met in chromophobe renal cell carcinoma.c-Met在嫌色性肾细胞癌中的作用
Med Oncol. 2017 Feb;34(2):15. doi: 10.1007/s12032-016-0874-1. Epub 2016 Dec 29.
5
Imaging features of renal complications after crizotinib treatment for non-small-cell lung cancer: a case report.克唑替尼治疗非小细胞肺癌后肾脏并发症的影像学特征:病例报告
Radiol Case Rep. 2016 May 18;11(3):245-7. doi: 10.1016/j.radcr.2016.04.010. eCollection 2016 Sep.
6
The renal effects of ALK inhibitors.ALK抑制剂对肾脏的影响。
Invest New Drugs. 2016 Oct;34(5):643-9. doi: 10.1007/s10637-016-0379-y. Epub 2016 Jul 29.
7
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.替凡替尼与索拉非尼联合用于晚期实体瘤成年患者的1期试验。
Invest New Drugs. 2015 Feb;33(1):159-68. doi: 10.1007/s10637-014-0167-5. Epub 2014 Oct 8.
8
Mutant p53 cooperates with knockdown of endogenous wild-type p53 to disrupt tubulogenesis in Madin-Darby canine kidney cells.突变型p53与内源性野生型p53的敲低协同作用,破坏了马-达二氏犬肾细胞中的管状结构形成。
PLoS One. 2013 Dec 27;8(12):e85624. doi: 10.1371/journal.pone.0085624. eCollection 2013.
9
Expression of the c-Met Proteins in Malignant Skin Cancers.c-Met蛋白在恶性皮肤癌中的表达
Ann Dermatol. 2011 Feb;23(1):33-8. doi: 10.5021/ad.2011.23.1.33. Epub 2011 Feb 28.
10
Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma.普利地昔(Aplidin)单药或与左旋肉碱联合用于不可切除的晚期肾细胞癌患者的II期随机研究。
Mar Drugs. 2009;7(1):57-70. doi: 10.3390/md7010057. Epub 2009 Mar 5.